Compare AU
Compare ITEK vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares Future Tech Innovators ETF (ITEK) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ITEK | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 81 |
Median incremental investment | $2,500.00 | $620.00 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $5,495.63 | $1,386.00 |
Average age group | > 35 | > 35 |
Key Summary
ITEK | CURE | |
|---|---|---|
Strategy | ITEK.AX was created on 2022-08-15 by iShares. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with the performance of the equally weighted return of the various indices of the Underlying Funds in which the Fund invests, before fees and expenses | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | ISHS ELEC VEHICLES DRVNG ETF USD A (17.14 %) ISH DIGITALTN ETF USD ACC (16.95 %) ISHARES AUTOMATION & ROBOTIC USD_D (16.86 %) | Neurocrine Biosciences Inc (2.58 %) AbbVie Inc (2.42 %) Gilead Sciences Inc (2.42 %) |
Top 3 industries | Other (99.97 %) Communication Services (0.00 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (53.40 %) Japan (7.60 %) China (4.56 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.63 % | 0.45 % |
Key Summary
ITEK | CURE | |
|---|---|---|
Issuer | iShares | Global X |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.63 % | 0.45 % |
Price | $29.31 | $49.49 |
Size | $5.874 million | $36.399 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.08 % | 4.24 % |
Market | ASX | ASX |
First listed date | 16/08/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ITEK | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 81 |
Median incremental investment | $2,500.00 | $620.00 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $5,495.63 | $1,386.00 |
Average age group | > 35 | > 35 |
Pros and Cons
ITEK | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ITEK | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |